

High-Risk Human Papillomavirus in Esophageal Squamous Cell Carcinoma—Response

Annika Antonsson¹, Derek J. Nancarrow², Ian S. Brown³, Adele C. Green¹, Paul A. Drew⁴, David I. Watson⁵, Nicholas K. Hayward², and David C. Whiteman¹

We thank Garland and colleagues for their interest in our study (1) and for raising the important issue of the sensitivity of the procedures we used to detect human papillomavirus (HPV) in esophageal squamous cell carcinoma (ESCC). More precisely, they have expressed concerns that our ability to detect HPV in ESCC tumor samples may have been compromised by degradation of DNA in formalin-fixed paraffin embedded (FFPE) tissue samples; modified MgCl₂ concentration; use of electrophoresis and sequencing instead of HPV type-specific probes; or potentially suboptimal histologic assessment of tumor samples. We have addressed each of these points below.

1. *Degradation of DNA.* We agree that internal controls of equal or longer length than the HPV amplicon would have been ideal to ensure that our samples contained longer sequences that could be amplified. However, we believe this potential source of bias is unlikely to explain our overall low rate of HPV detection, as DNA is known to be very stable (even in FFPE tissue), and the samples analyzed in our study were all collected recently (between 4–8 years old; refs. 2, 3). Furthermore, the 2 primer pairs GP5⁺/6⁺ and PCO3/PCO4 were designed to be used in combination to screen FFPE tissues for the presence of HPV and have been used in previous published studies (4–7).
2. *Change in MgCl₂ concentration.* We used a lower MgCl₂ concentration (2.0 mmol/L) than other reports (3.5 mmol/L). We have tested the sensitivity of the GP5⁺/6⁺ primer pair at the lower concentration and can detect down to 10 copies for certain HPV types including HPV-16 and HPV-18 (unpublished data). Furthermore, other studies (8, 9) have also used 2.0 mmol/L in their GP5⁺/6⁺ PCR and

Chao and colleagues (8) report a similar sensitivity to ours (100 HPV copies detected).

3. *Use of electrophoresis and sequencing instead of HPV type-specific probes.* Our detection threshold was 10 HPV copies per sample for some HPV types (HPV-16 and HPV-18). It is questionable whether higher HPV sensitivity could be achieved using probes, which would likely come at the cost of lower specificity. A particular advantage of the sequencing strategy that we employed is the avoidance of cross-reactivity problems that are common when using probes (10). Finally, it must be considered whether detection thresholds of less than 10 HPV copies per sample are clinically important (11).
4. *Histologic screening and sample suitability for PCR.* The tumor samples used in our study were all confirmed histologically as ESCC by an expert gastrointestinal pathologist (I.S.B.) using a section cut adjacent to the unstained sections used for DNA extraction. We did not confirm the existence of ESCC tumor in a second section on the other side of the unstained section, although this is a highly unlikely source of error given the large size of the tumors in this series. Also, the overall low prevalence of HPV we detected would have changed little had we chosen exclude the 22 ESCC samples on slides (4.0% compared with 3.6%).

Thus, while we agree that methodologic issues must be considered as possible explanations for the overall very low prevalence of HPV DNA in ESCC tumor samples, we do not believe that low sensitivity explains the findings. The varying HPV prevalences reported in published ESCC studies are most likely explained by variations in laboratory technique and differences in sampling strategies for patients and tissues. These scientific issues require resolution before any public health implications can be addressed.

Authors' Affiliations: ¹Genetics and Population Health Division and ²Oncogenomics, Queensland Institute of Medical Research, Brisbane, Queensland, Australia, ³Sullivan Nicolaides Pathology and Royal Brisbane and Women's Hospital Brisbane, Brisbane, Queensland, Australia, ⁴School of Nursing and Midwifery and ⁵Department of Surgery, Flinders University, Bedford Park, South Australia, Australia

doi: 10.1158/1055-9965.EPI-10-1287

©2011 American Association for Cancer Research.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Received September 12, 2010; accepted September 12, 2010; published online February 7, 2011.

References

1. Antonsson A, Nancarrow DJ, Brown IS, Green AC, Drew PA, Watson DI, et al. High-risk human papillomavirus in esophageal squamous cell carcinoma. *Cancer Epidemiol Biomarkers Prev* 2010;19:2080–7.
2. Greer CE, Wheeler CM, Manos MM. Sample preparation and PCR amplification from paraffin-embedded tissues. *PCR Methods Appl* 1994;3:S113–22.
3. Hewitt SM, Lewis FA, Cao Y, Conrad RC, Cronin M, Danenberg KD, et al. Tissue handling and specimen preparation in surgical pathology: issues concerning the recovery of nucleic acids from formalin-fixed, paraffin-embedded tissue. *Arch Pathol Lab Med* 2008;132:1929–35.
4. de RodaHusman AM, Walboomers JM, Hopman E, Bleker OP, Helmerhorst TM, Rozendaal L, et al. HPV prevalence in cytomorphologically normal cervical scrapes of pregnant women as determined by PCR: the age-related pattern. *J Med Virol* 1995;46:97–102.
5. Nonogaki S, Wakamatsu A, Filho AL, Roteli-Martins C, di Loreto C, Maeda MY, et al. Molecular strategies for identifying human papillomavirus infection in routinely processed samples: focus on paraffin sections. *J Low Genit Tract Dis* 2005;9:219–24.
6. Soares RC, Oliveira MC, Souza LB, Costa AL, Medeiros SR, Pinto LP. Human papillomavirus in oral squamous cells carcinoma in a population of 75 Brazilian patients. *Am J Otolaryngol* 2007;28:397–400.
7. Smeets SJ, Hesselink AT, Speel EJ, Haesevoets A, Snijders PJ, Pawlita M, et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. *Int J Cancer* 2007;121:2465–72.
8. Chao FY, Chao A, Huang CC, Hsueh S, Yang JE, Huang HJ, et al. Defining detection threshold and improving analytical proficiency of HPV testing in clinical specimens. *Gynecol Oncol* 2010;117:302–7.
9. Wang X, Tian X, Liu F, Zhao Y, Sun M, Chen D, et al. Detection of HPV DNA in esophageal cancer specimens from different regions and ethnic groups: a descriptive study. *BMC Cancer* 2010;10:19.
10. Tabrizi SN, Taylor N, McCullough MJ, Phillips G, Wark J, Gertig D, et al. Human papillomavirus genotype detection from archival papanicolaou-stained cervical tests. *Cancer Cytopathol* 2010;118:482–9.
11. Koshiol J, Wei WQ, Kreimer AR, Chen W, Gravitt P, Ren JS, et al. No role for human papillomavirus in esophageal squamous cell carcinoma in China. *Int J Cancer* 2010;127:93–100.